Universal Biosensors, Inc. (ASX: UBI) has signed a distribution partnership with Henry Schein, Inc., a leading U.S. distributor of medical and coagulation products, for its Xprecia Prime™ Coagulation Analyzer. This agreement makes Henry Schein the first U.S. distributor for Xprecia Prime, a compact device that provides fast and accurate prothrombin time (PT) and International Normalized Ratio (INR) results.
This partnership will give thousands of U.S. coagulation clinics and hospitals access to Xprecia Prime through Henry Schein’s extensive network. CEO John Sharman expressed excitement, highlighting recent efforts to expand UBI's presence in the U.S. market and noted that additional distribution agreements are being pursued. UBI specializes in biosensor technology for healthcare and other industries, with a focus on creating products for large markets to ensure continuous revenue growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Dec 13, 2024
Dec 13, 2024
Dec 13, 2024
Dec 13, 2024
Dec 13, 2024
Dec 13, 2024
Dec 12, 2024
Dec 12, 2024
Dec 12, 2024
Dec 12, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.